AstraZeneca PLC (AZN)

AZN (NYSE:Drugs)
$63.49
neg -0.04
-0.06%
Today's Range: 63.25 - 63.75 | AZN Avg Daily Volume: 2,316,600
Last Update: 04/17/14 - 4:00 PM EDT
Volume: 1,033,896
YTD Performance: 6.94%
Open: $63.64
Previous Close: $63.53
52 Week Range: $46.87 - $68.76
Oustanding Shares: 1,257,170,087
Market Cap: 79,868,015,627
6-Month Chart
TheStreet Ratings Grade for AZN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 3 3 5 5
Moderate Sell 1 1 0 0
Strong Sell 1 1 0 0
Mean Rec. 2.86 2.86 2.43 2.43
Latest Dividend: 1.90
Latest Dividend Yield: 4.23%
Dividend Ex-Date: 02/19/14
Price Earnings Ratio: 13.26
Price Earnings Comparisons:
AZN Sector Avg. S&P 500
13.26 31.20 29.01
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.38% 24.98% 28.68%
GROWTH 12 Mo 3 Yr CAGR
Revenue -8.10 -0.23 -0.08
Net Income -59.40 -0.68 -0.31
EPS -59.10 -0.64 -0.28
Earnings for AZN:
EBITDA 7.70B
Revenue 25.71B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $1.20 $1.09 $4.32 $4.26
Number of Analysts 3 2 6 6
High Estimate $1.25 $1.11 $4.48 $4.39
Low Estimate $1.16 $1.07 $4.24 $4.10
Prior Year $1.41 $1.20 $5.05 $4.32
Growth Rate (Year over Year) -15.13% -9.17% -14.49% -1.31%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
The UK is the next geographic hotspot. Play it with this ETF.
These four names in particular have made some stunning moves.
Bearish
Apr 08, 2013 | 8:30 AM EDT
AZN estimates were reduced through 2014, Leerink Swann said. Cautious feedback for Fostamatinib lowers the chance for FDA approval.&nbs...
These companies are performing like champions, despite a weak British economy.

Stephanie Link, director of research at TheStreet, eliminated her position in Abbott to build a position in Bristol Meyers.

Adam Feuerstein, Sr. Columnist for TheStreet, says M&A is the next big thing in biotech.

European headlines worried traders ahead of the open, as they await a raft of economic and retail reports.
Net-cash stocks can be the Christmas gifts that keep on giving.
The sector is in the doldrums, yet the prospects for these three names are quite strong.
Forget about hitting home runs and focus on avoiding strikeouts.

Columnist Conversations

There were nice reversal-type candles on the weekly charts of the major indices. The DOW and the S&P forme...
A number of stocks on my watch lists are attempting to form positive candles a key support levels. I noted th...
Lang:
While last week was a day to pull the plug and contemplate where the market was headed, I waited for some conf...
Shares of TSLA have formed multiple hammer candles at a key level of support defined by: the September head an...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.